-
Media ReleaseNPC Statement on Comments Made in Media Coverage of Paycheck Fairness Act
-
Media ReleaseTwo new analyses reinforce consistent efficacy of Novartis therapy Gilenya across wide range of relapsing MS patients
-
Media ReleaseTV host Phil Keoghan and professional women cyclists join Novartis to raise awareness of multiple sclerosis
-
Media ReleaseHigher dose of Novartis drug Exelon® Patch showed statistically significantly less decline in function in Alzheimer’s vs. lower dose
-
Media ReleaseNew extension study data with Novartis drug Gilenya shows patients successfully treated for up to 7 years in relapsing MS
-
Media ReleaseNovartis announces update to United States prescribing information for MS therapy Gilenya following FDA review
-
Media ReleaseNovartis expands transplant portfolio with Hecoria®, the first generic tacrolimus that can be prescribed by brand name
-
Media ReleaseNovartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease
-
Media ReleasePlaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
-
Media ReleaseNovartis Pivotal Study of Exjade® Shows Significant Reduction of Iron Overload in Patients with Non-transfusion-dependent Thalassemia
-
Media ReleaseTwo Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
-
Media ReleaseNovartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis